Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib plus carboplatin and paclitaxel versus placebo plus carboplatin and paclitaxel in advanced or metastatic squamous non-small-cell lung cancer
2013-005020-42Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pulmonary squamous cell carcinoma comparing Veliparib + carboplatin + paclitaxel with Placebo + carboplatin + paclitaxel (2 arms). Primary endpoint: Overall Survival (OS) in current smokers. Started Mar 2014; status: completed.
02
Drugs
veliparib
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2013-005020-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005020-42.